Nemera announces the appointment of Véronique Kodjo as non-Executive member of the board
27/05/2021
![New member board - december 2020](https://www.nemera.net/wp-content/uploads/2021/05/POST-new-member-board.jpg)
Nemera, world leader in design, development and manufacturing of drug device combination solutions for the pharmaceutical, biotechnology and generic industries, today announced the appointment of senior leader Véronique Kodjo as a non-Executive member of its Board. She will work closely with the Chief Operating Officer and senior leadership to accompany Nemera on its journey toward operational excellence.
Marc Hämel, CEO of Nemera said, “We are thrilled to welcome Véronique to Nemera. Véronique’s decades of leadership in global operations and supply chain complemented by her expertise in the pharmaceutical industry adds a strong new voice to the Board. Her contribution will further enhance our decision-making and help reinforce our commitment to patients, customers and other stakeholders. This is also a solid proofpoint of our conviction to gender balance and diversity”.
“Nemera’s vision of becoming the most patient-centric drug device combination solutions company resonates with me personally. This is an exciting opportunity and I look forward to working with passionate and high-performing people at Nemera”, said Véronique Kodjo.
Véronique will continue to serve as Executive Vice-President of Global Manufacturing, Supply Chain and Quality at Ceva Santé Animale, a leading veterinary healthcare with sales of more than €1,2bn, 25 production sites and 12 R&D centres worldwide. In her different roles with various companies, she has designed and implemented a group-wide industrial strategy including review of the footprint structure to increase industrial efficiency. Prior to Ceva, Véronique was part of Boehringer Ingelheim, Merial & Zeneca Pharmaceuticals.
To dowload the press release: New_Board_Member_PR
About Nemera
As a world-leading drug device combination solutions specialist, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are the utmost holistic partner and help our customers succeed in the sprint to market. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.
For more information, visit www.nemera.net